X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The financing aims to fund the clinical development of SENS-501 (OTOF-GT) small molecule programs for the treatment and prevention of hearing loss disorders.
Lead Product(s): OTOF-GT
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: SENS-501
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Redmile Group
Deal Size: $16.2 million Upfront Cash: Undisclosed
Deal Type: Financing April 08, 2024
Details:
SENS-401 (arazasetron) is an orally available 5-HT3 receptor antagonist, small molecule drug. It is being evaluated in phase 2 clinical trials for the treatment of hearing loss.
Lead Product(s): R-Azasetron Besylate
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: SENS-401
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 11, 2024
Details:
Through financing, Sensorion will prioritize the development of SENS-501 ( OTOF-GT), which aims to restore hearing in individuals with Otoferlin deficiency, a prevalent form of congenital deafness.
Lead Product(s): OTOF-GT
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: SENS-501
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Redmile Group
Deal Size: $54.4 million Upfront Cash: Undisclosed
Deal Type: Financing February 09, 2024
Details:
SENS-401 (arazasetron) is an orally available 5-HT3 receptor antagonist, small molecule drug. It is being evaluated in phase 2 clinical trials for the treatment of hearing loss.
Lead Product(s): R-Azasetron Besylate
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: SENS-401
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 01, 2024
Details:
SENS-501 (OTOF-GT) dual vector AAV gene therapy development program aims to restore hearing in patients with mutations in the gene coding for otoferlin protein who suffer from severe to profound sensorineural prelingual non-syndromic hearing loss.
Lead Product(s): OTOF-GT
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: SENS-501
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2024
Details:
Sensorion and Institut Pasteur will focus on the development of two gene therapy programs, including SENS-501 (OTOF-GT), which targets deafness caused by mutations of the gene encoding for otoferlin and GJB2-GT, which targets hearing loss related to mutations in GJB2 gene.
Lead Product(s): SENS-501
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: OTOF-GT
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Institut Pasteur
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 05, 2024
Details:
SENS-401 (Arazasetron) is a 5-HT3 receptor antagonist and calcineurin inhibitor, orally available small molecule, which is under phase 2 clinical development for the treatment of Cisplatin-Induced Ototoxicity (CIO).
Lead Product(s): R-Azasetron Besylate
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: SENS-401
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 18, 2023
Details:
OTOF-GT is a dual AAV vector gene therapy development program aims to restore hearing in patients with mutations in OTOF who suffer from severe to profound sensorineural prelingual non syndromic hearing loss.
Lead Product(s): SENS-501
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: OTOF-GT
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 19, 2023
Details:
OTOF-GT is a dual AAV vector gene therapy development program aims to restore hearing in patients with mutations in OTOF who suffer from severe to profound sensorineural prelingual non syndromic hearing loss.
Lead Product(s): OTOF-GT
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: OTOF-GT
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2023
Details:
SENS-501 is an adeno-associated vector-based gene therapy for the autosomal recessive non-syndromic Deafness 9. It is being investigated in preclinical stage for DFNB9.
Lead Product(s): SENS-501
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: SENS-501
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 02, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
